statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beyond The Numbers: 4 Analysts Discuss NovoCure Stock

Latest Ratings for NVCR
 DateFirmActionFromTo Feb 2022Loop CapitalInitiates Coverage OnBuy Feb 2022OppenheimerUpgradesPerformOutperform Jan 2022Truist SecuritiesUpgradesHoldBuy
 View More...

Novocure Reports Second Quarter 2024 Financial Results

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of...

CereVasc Announces Appointments of New Directors

CereVasc Announces Appointments of New Directors CereVasc Announces Appointments of New Directors PR Newswire BOSTON, July 16, 2024 Medical Device LeadersShlomi Nachman and Timothy Scannell to join...

Novocure to Report Second Quarter 2024 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will...

Cramer's Lightning Round: Novocure, PayPal, AeroVironment

Cramer's Lightning Round: Novocure, PayPal, AeroVironment...

A Closer Look at 7 Analyst Recommendations For NovoCure

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Fields (TTFields) therapy in the treatment of...

TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany

Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the...

Unveiling 8 Analyst Insights On NovoCure

Futures Rise As Dovish Fed Boosts Sentiment, Reverse Bizarre Post-Powell Slide

Futures Rise As Dovish Fed Boosts Sentiment, Reverse Bizarre Post-Powell Slide

 After a bizarre reversal when US stocks first slumped and then dumped after Powell's very dovish FOMC...

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Volume	1.24M
52-Wk High	$35.10
52-Wk Low	$10.87

NVCR NovoCure Ltd

About

Feed

News

Sentiment

Earnings

Fundamentals